Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

NCT06429787 · clinicaltrials.gov ↗

RECRUITING

Status

3574

Enrollment

INDUSTRY

Sponsor class

Conditions

Vitamin K-Dependent Coagulation Defect
Significant Bleeding Risk

Interventions

DRUG: Balfaxar
DRUG: Kcentra

Sponsor

Octapharma